Latest Insider Transactions at Acrivon Therapeutics, Inc. (ACRV)
This section provides a real-time view of insider transactions for Acrivon Therapeutics, Inc. (ACRV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Acrivon Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Acrivon Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2022
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Conversion of derivative security
|
Direct |
888,130
+50.0%
|
-
|
|
Nov 14
2022
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
26,707
+7.69%
|
-
|
|
Nov 14
2022
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,498,240
+18.15%
|
-
|
|
Nov 14
2022
|
Kristina Masson EVP - Business Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
1,498,240
+18.15%
|
-
|
|
Nov 14
2022
|
Kristina Masson EVP - Business Operations |
BUY
Grant, award, or other acquisition
|
Direct |
26,707
+7.69%
|
-
|
|
Nov 14
2022
|
Rasmus Holm Jorgensen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,030
+50.0%
|
-
|
|
Nov 14
2022
|
Eric Devroe Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,383
+38.35%
|
-
|
|
Nov 14
2022
|
Erick Gamelin Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,030
+50.0%
|
-
|